Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Zeitler

Otology & Neurotology Seattle, WA Medical Doctor

NPI 1154525012 CMS profile 7485

1100 9Th Ave, Seattle, WA 98101

Open in the dashboard

General payments

$235,739

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,340,873 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Daniel Zeitler of Seattle, WA is reported in the CMS Open Payments database as having received $235,739 across 258 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,340,873 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,359 27
2024 General $109,710 48
2023 General $94,329 40
2022 General $5,495 41
2021 General $3,689 33
2020 General $549 17
2019 General $11,607 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Zeitler
  • Otology & Neurotology median
  • Middle half of Otology & Neurotology
  • National median

In program year 2025, general payments to Daniel Zeitler were reported at $10,359. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.

Show as a table
Year Daniel Zeitler Otology & Neurotology median Middle half National median
2019 $11,607 $349 $117–$1,358 $163
2020 $549 $118 $58–$325 $114
2021 $3,689 $186 $81–$600 $132
2022 $5,495 $290 $129–$938 $149
2023 $94,329 $335 $119–$978 $160
2024 $109,710 $399 $138–$1,384 $164
2025 $10,359 $411 $148–$1,608 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cochlear Americas $205,030 100 payments
  2. MED-EL Corporation $18,667 54 payments
  3. Advanced Bionics, LLC $7,940 63 payments
  4. Stryker Corporation $2,853 32 payments
  5. Oticon Medical, LLC $549 2 payments
  6. Grace Medical, Inc. $376 3 payments
  7. Medtronic, Inc. $277 3 payments
  8. Merz Pharmaceuticals, LLC $45 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $200,391 20 payments
  2. Travel and Lodging $14,248 54 payments
  3. Food and Beverage $12,150 181 payments
  4. Honoraria $8,950 3 payments
Products named General payments · program years 2019–2025
  1. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $202,151 75 payments
  2. BAHA $200,551 74 payments
  3. OSIA OSI300 IMPLANT $199,958 65 payments
  4. Mi1250 SYNCHRONY 2 FLEXsoft $13,293 42 payments
  5. BCI 602 Kit $12,584 31 payments
  6. ADHEAR Professional Kit $8,902 16 payments
  7. MED-EL Maestro Cochlear Implant System $5,331 10 payments
  8. VIBRANT Soundbridge Middle Ear Implant and BONEBRIDGE System $5,039 7 payments
  9. HIRES ULTRA CI HIFOCUS MS ELECTRODE $4,776 30 payments
  10. HiResolution Bionic Ear System $2,970 26 payments
  11. Other $14,752 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

66

Median for Otolaryngology: 297

Drug cost

$2,114

Median for Otolaryngology: $6,314

Branded share of claims

24.2%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofloxacin Generic 38 $1,096
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 16 $996
Oxycodone Hcl Generic 12 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$48,090

Medicare's payments for the services billed

Medicare patients

197

Average age 76

Services billed

340

96 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 38%
Ischemic heart disease 19%
Osteoporosis 17%
Diabetes 16%
Cancer 16%
Depression 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otology & Neurotology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record